MADISON, Wis., May 13, 2026 — Axio BioPharma today announced the launch of its new industry eBook, “AI in Biomanufacturing: How Operating Models, Digital Twins, and Federated Intelligence are Reshaping the Biologics Manufacturing Ecosystem.” The report provides a 2026–2029 outlook on how artificial intelligence is expected to transform biologics manufacturing, and why many organizations must first address deeper operational, digital, and governance gaps before AI can scale meaningfully. Download the report and join the BAMI Assessment Waitlist at: https://axiobiopharma.com/bami.
Read more →
Madison, WI (February 3, 2026) — Axio BioPharma, an AI-ready biologics contract development and manufacturing organization (CDMO), today announced it has been selected as a Round 1 awardee of the Innovation to Commercialization Pipeline (ICP) program, led by Forward BIOLABS in partnership with BioForward Wisconsin.
Read more →
MADISON, Wis., June 16, 2025 -- Axio BioPharma Inc., a next-generation biomanufacturing company using AI to transform mammalian protein production, today announced the continued expansion of its advisory board with the recent addition of Patrick Haffey. He joins existing advisors Dr. Greg Bleck and Dr. Graham Brearley, forming a deeply experienced group of leaders in biologics research, development, and operations.
Read more →Occasional notes on biologics, AI-driven process development, and what the team is building. No marketing fluff.
